Plain-English translation of NCT06867094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help people with moderate-to-severe ulcerative colitis — a condition where the colon becomes inflamed and causes pain, bleeding, and diarrhea. Researchers will compare three different doses of the medication against a placebo to find out which dose works best and is safest. About 204 patients will participate across multiple hospitals worldwide.
Many people with ulcerative colitis don't respond well enough to current treatments, or they lose the benefit over time. This trial is testing whether this new medication could offer a better option for people who haven't found relief with standard or advanced treatments.
You likely qualify if…
You likely don't qualify if…
If you're accepted, you'll first have a screening period of up to 4 weeks to confirm you have ulcerative colitis. Then you'll enter the main study for 52 weeks: the first 12 weeks will focus on getting your disease under control (induction), followed by 40 weeks of maintenance treatment to keep it controlled. You'll receive either one of three doses of the new medication or a placebo by random assignment, and you won't know which one you're getting. You'll have about 12 study visits during this time for check-ups, blood tests, and sometimes endoscopy to monitor your progress.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States